approval of STROMECTOL® represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for STROMECTOL® is 2,291 days. Of this time, 2,055 days occurred during the testing phase of the regulatory review period, while 236 days occurred during the approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective*: August 17, 1990. The applicant claims July 17, 1990, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was August 17, 1990, which was 30 days after FDA receipt of the IND.

2. *The date the application was initially submitted with respect to the human drug product under section 505 of the act*: April 1, 1996. The applicant claims March 29, 1996, as the date the new drug application (NDA) for STROMECTOL® (NDA 50–742) was initially submitted. However, FDA records indicate that NDA 50–742 was submitted on April 1, 1996.

3. *The date the application was approved*: November 22, 1996. FDA has verified the applicant's claim that NDA 50–742 was approved on November 22, 1996.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,026 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before September 8, 1998, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before January 6, 1999, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 23, 1998.

Thomas J. McGinnis,

Deputy Associate Commissioner for Health Affairs.

[FR Doc. 98–18400 Filed 7–9–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97E–0359]

Determination of Regulatory Review Period for Purposes of Patent Extension; Flowmax™

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for Flowmax™ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6620.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: a testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product Flowmax™ (tamsulosin hydrochloride). Flowmax™ is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for Flowmax™ (U.S. Patent No. 4,868,216) from Yamanouchi Pharmaceutical, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated November 7, 1997, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of Flowmax™ represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that the FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for Flowmax™ is 3,529 days. Of this time, 3,163 days occurred during the testing phase of the regulatory review period, 366 days occurred during the approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective*: August 19, 1987. FDA has verified the applicant's claim that the date the investigational new

drug application became effective was on August 19, 1987.

2. *The date the application was initially submitted with respect to the human drug product under section 505 of the act*: April 15, 1996. FDA has verified the applicant's claim that the new drug application (NDA) for Flowmax™ (NDA 20–579) was initially submitted on April 15, 1996.

3. *The date the application was approved:* April 15, 1997. FDA has verified the applicant's claim that NDA 20–579 was approved on April 15, 1997.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,669 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before September 8, 1998, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before January 6, 1999, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 23, 1998.

Thomas J. McGinnis,

Deputy Associate Commissioner for Health Affairs.

[FR Doc. 98–18407 Filed 7–9–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antimicrobial Drugs and Resistance; Notice of Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting to discuss the development of drug products for the treatment of resistant bacteria, including selective spectrum agents. The purpose of the meeting is to provide information on the agency's plans for future public scientific discussions of issues unique to the development of these drug products and to invite members of the public to provide comments on the agency's plans.

DATES: The public meeting will be held on Tuesday, July 28, 1998, from 2 p.m. to 6 p.m.

ADDRESSES: The public meeting will be held in conference rooms G and H, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Thomas H. Hassall, Center for Drug Evaluation and Research (HFD–104), Food and Drug Administration, 9201 Corporate Blvd., Rockville, MD 20850, 301–827–2489.

SUPPLEMENTARY INFORMATION: FDA will hold a public meeting on July 28, 1998, to discuss its plans for a presentation at a fall 1998 advisory committee meeting and possible future meetings on the development of drug products to treat resistant bacteria, including selective spectrum agents. At the fall 1998 advisory committee meeting, FDA plans to discuss issues unique to the development of such products, including clinical trial design and labeling issues. At the meeting, FDA will present its thoughts on the issues that should be presented to the advisory committee and will solicit public input on the structure of the discussion and additional issues that should be presented.

There is no registration for this meeting, however, space is limited. Persons interested in attending the meeting should contact the person listed above.

An agenda for the public meeting will be available 2 weeks before the meeting, via the Internet using the World Wide Web (WWW). To connect to the CDER home page, type ''http://www.fda.gov/cder'' and go to the ''What's Happening'' section.

Dated: July 3, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–18397 Filed 7–9–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

1998 FDA Science Forum—Biotechnology: Advances, Applications, and Regulatory Challenges

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration's (FDA's) Office of Science is announcing the following meeting: ''1998 FDA Science Forum—Biotechnology: Advances, Applications, and Regulatory Challenges.'' The Forum will bring FDA research and review scientists together with representatives of industry, academia, Government agencies, consumer groups, and the public to discuss the impact of the enormous advances in biotechnology on product development and regulation.

Date and Time: The meeting will be held on Tuesday and Wednesday, December 8 and 9, 1998; registration from 7:00 a.m. to 8:30 a.m.; meeting from 8:30 a.m. to 6:00 p.m. on December 8, and 8:30 a.m. to 5:00 p.m. on December 9.

Location: The meeting will be held at the Washington Convention Center, rms. 29–32 (lower level) and Hall C (upper level) 900 Ninth Street, NW., Washington, DC 20001.

Contact: American Association of Pharmaceutical Scientists at <meetings@aaps.org>, 703–518–8429, or Susan A. Homire, Food and Drug Administration, Office of Science (HF–32), 5600 Fishers Lane, Rockville, MD, 20857, 301–827–3366, e-mail <shomire@bangate.fda.gov>.

Registration: Registration information will be available in mid-July. Attendance will be limited; therefore, interested parties are encouraged to register early.

If you need special accommodations due to a disability, please contact the American Association of Pharmaceutical Scientists at least 3 weeks in advance.

Agenda: The program will encompass bioengineered products, novel therapeutic and preventive approaches, diagnostics and detection methodologies, and safety and efficacy